Transient Hypnic Headache Syndrome in a Patient With Bipolar Disorder After the Withdrawal of Long-Term Lithium Treatment: A Case Report

Cephalalgia ◽  
2009 ◽  
Vol 29 (4) ◽  
pp. 484-486 ◽  
Author(s):  
A Karlovasitou ◽  
E Avdelidi ◽  
G Andriopoulou ◽  
S Baloyannis
2021 ◽  
Vol 37 (2) ◽  
Author(s):  
Przemysław Filipiak ◽  
Anna Jaskóła ◽  
Karolina Gattner

Objectives. Psoriasis makes a relative contraindication for lithium treatment which can exacerbate its symptoms or induce it itself. On the other hand, lithium exerts immuno-modulatory activity. Case study. In this paper, a case of a female patient is presented. The patient has been treated since 2012 for bipolar affective illness (bipolar disorder – BD) and psori­asis, which occurred for the first time during a depress­ive episode. Despite intensive pharmacological treatment, both as inpatient and outpatient, a satisfactory improvement of affective illness has not been obtained. After the introduction of lithium, a remission of BD was achieved as well as a reduction of psoriatic changes, which have been maintained until now (2021). Conclusion. The remission of Bipolar Disorder (BD) on lithium can suggest that the patient belongs to the group of the so-called excellent lithium responders. In the presen­ted case remission of psoriasis was observed during lithium treatment. This case report must be treated with caution because remission could be spontaneous and the patient needs further observation.


2021 ◽  
Vol 281 ◽  
pp. 228-234
Author(s):  
R. Queissner ◽  
M. Lenger ◽  
A. Birner ◽  
N. Dalkner ◽  
F. Fellendorf ◽  
...  

2007 ◽  
Vol 195 (3) ◽  
pp. 357-367 ◽  
Author(s):  
Kaan Yucel ◽  
Margaret C. McKinnon ◽  
Valerie H. Taylor ◽  
Kathryn Macdonald ◽  
Martin Alda ◽  
...  

2016 ◽  
Vol 18 (1) ◽  
pp. 54-62 ◽  
Author(s):  
Ewa Ferensztajn-Rochowiak ◽  
Jolanta Kucharska-Mazur ◽  
Jerzy Samochowiec ◽  
Mariusz Z. Ratajczak ◽  
Michal Michalak ◽  
...  

2021 ◽  
pp. 1-25
Author(s):  
Ewa Ferensztajn-Rochowiak ◽  
Ewa Kurczewska ◽  
Błażej Rubiś ◽  
Michalina Lulkiewicz ◽  
Hanna Hołysz ◽  
...  

Abstract Objectives: Bipolar disorder (BD) may be connected with accelerated aging, the marker of this can be shorter telomere length (TL). Some data suggest that lithium may exert a protective effect against telomere shortening. The study aimed to compare the telomere length between patients with bipolar disorder and control subjects. The effect of long-term lithium treatment was also assessed. Methods: The study group comprised 41 patients with BD, including 29 patients treated longitudinally with lithium (mean 16.5 years) and 20 healthy people. Telomere length was assessed by the quantitative polymerase chain reaction (qPCR). Results: In the control group, the TL was significantly longer in males than in females. Male bipolar patients had significantly shorter TL compared with the control male group. In bipolar patients, there was no correlation between TL and duration of treatment. The TL was negatively correlated with age in male bipolar patients. Conclusion: The study did not confirm the lithium effect on TL in bipolar patients. TL showed gender differences, being shorter in BD males, compared to control males, and longer in healthy males, compared to control females.


2016 ◽  
Vol 33 (S1) ◽  
pp. S392-S392 ◽  
Author(s):  
S. López-Romeo ◽  
G. Ledesma-Iparraguirre

IntroductionLithium is currently a drug of choice for treating persons with bipolar disorder and is widely used in this population. Approximately, 30% of patients taking lithium experience at least one episode of lithium toxicity. Treatment of acute toxicity involves correction of electrolyte abnormalities, volume repletion followed by forced diuresis, and dialysis in severe cases. A case report is described and it is reviewed some alternative treatment options before considering withdrawal of lithium treatment in lithium-induced nephrogenic diabetes insipidus.Case reportA 58-year-old woman diagnosed of hypertension and bipolar disorder for 20 years. At first, she was controlled with valproic acid until she suffered a manic episode which required a mood stabilizer switch. She started a treatment with lithium 1200 mg/day and olanzapine to 10 mg/day and was completely recovered. After a year of stabilization, olanzapine was retired and she maintained stabilized with lithium 1000 mg/day during last 17 years. During last 8 months, she suffered polydipsia and polyuria (4 L/day). She was diagnosed of nephrogenic diabetes insipidus. Some measures like liquid restriction, lithium monodose and low sodium diet were carried out, obtaining a partial response. Taking into account, she was stabilised with lithium for many years, it was decided to introduce hydrochlorothiazide 25 mg/day, clinical and analytical resolution of nephrogenic diabetes insipidus was obtained. A year later, she maintains psychopathological stabilization, without any lithium secondary effects.ConclusionSome treatment options for lithium-induced nephrogenic diabetes insipidus could be introducing thiazides, amiloride, indomethacin, desmopressin or carbamazepine, instead of withdrawal lithium.Disclosure of interestThe authors have not supplied their declaration of competing interest.


2017 ◽  
Vol 13 (1) ◽  
pp. 43-48
Author(s):  
Julia Dehning ◽  
Heinz Grunze ◽  
Armand Hausmann

Background:The optimal duration of antidepressant treatment in bipolar depression appears to be controversial due to a lack of quality evidence, and guideline recommendations are either vague or contradictive. This is especially true for second line treatments such as bupropion that had not been subject to rigourous long term studies in Bipolar Disorder.Case presentation:We report the case of a 75 year old woman who presented with treatment refractory bipolar depression. Because of insufficient response to previous mood stabilizer treatment and refractory depressive symptoms, bupropion was added to venlafaxine and lamotrigine. From there onwards, the patient improved continuously without experiencing deterioration of depression or a switch into hypomania. Our patient being on antidepressants for allmost four years experienced an obvious benefit from longterm antidepressant administration.Conclusion:Noradrenergic/dopaminergic mechanisms of action may play a more prominent role in bipolar depression, and may still be underused as a therapeutic strategy in the acute phase as well as in long-term maintenance in at least a subgroup of bipolar patients. There is still a lack of evidence from RCTs, but this case report further supports antidepressant long-term continuation and the usefulness of a noradrenergic/dopaminergic antidepressant in the acute and maintenance treatment of bipolar disorder.


Sign in / Sign up

Export Citation Format

Share Document